Recombinant Human ACLP His-tag Protein, CF

When Recombinant Human LRP-6 Fc Chimera (Catalog # 1505-LR) is coated at 2 μg/mL, 100 μL/well, Recombinant Human ACLP (Catalog # 6425-AC) binds with an ED50 of 1‑8 μg/mL.

2 μg/lane of Recombinant Human ACLP His-tag (Catalog# 6425-AC) was resolved with SDS-PAGE underreducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Bluestaining, showing bands at 160-180 kDa.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human ACLP His-tag Protein, CF Summary

• Additional Information: ACLP activates canonical WNT/Beta-catenin signaling through Frizzeld-8 and LRP-6
• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human LRP-6 Fc Chimera (Catalog # 1505-LR) is coated at 2 ug/mL, 100 uL/well, Recombinant ACLP binds with an ED₅₀ of 1-8 μg/mL.
• Source: Human embryonic kidney cell, HEK293-derived human ACLP protein
  Gln26-Phe1158, with a C-terminal 10-His tag
• Accession #: Q8IUX7
• N-terminal Sequence: No results obtained. Gln26 inferred from enzymatic pyroglutamate treatment revealing Thr27.
• Protein/Peptide Type: Recombinant Proteins
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 130 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 160-180 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human ACLP His-tag Protein, CF

• ACLP
• ACLPadipocyte enhancer binding protein 1
• AE binding protein 1
• AE-binding protein 1adipocyte enhancer-binding protein 1
• AEBP1
• Aortic carboxypeptidase-like protein
• FLJ33612

Background

Aortic carboxypeptidase-like protein (ACLP), also known as adipocyte enhancer binding protein (AEBP1) (1, 2), is a secreted ECM-associated protein expressed primarily by perivascular and vascular cells and is up-regulated in activated vascular cells following vascular injury (3). Pro-ACLP is composed of an N-terminal signal sequence that is cleaved off in the mature form, a Lys/Pro rich motif (aa 47-326), a Glu rich motif (aa 1079-1136), a collagen binding discoidin-like domain (aa 383-540) and a peptidase-like domain (aa 560-942) (4, 5). Mature human ACLP shares 84% aa sequence identity with mouse and rat ACLP. In the liver, ACLP is specifically expressed in hepatic stellate cells (HSCs). Although unrelated to WNT proteins, ACLP can specifically bind to Frizzled-8 and Lrp6 to form a ternary complex to activate the canonical WNT pathway and exacerbates nonalcoholic steatohepatitis (NASH) pathology, indicating that NASH can be treated by targeting ACLP (6). Diseases associated with ACLP-1 include Ehlers-Danlos syndrome classic-like 2 (EDSCLL2) (7) and gastroschisis. Over-expression of ACLP-1 is associated with glioblastoma (8).

1. He, G.P. et al.(1995) Nature. 378: 92.
2. Ro, H.S. et al. (2001) Gene. 280:123.
3. Layne, M.D. et al. (2002) Cir. Res. 90:728.
4. Tumelty, K.E. et al. (2014) J. Biol. Chem. 289:2526.
5. Layne, M.D. et al. (1998) J. Biol. Chem. 273:15654.
6. Teratani, T. et al. (2018) J Clin Invest. 128:1581.
7. Blackburn, P.R. et al. (2018) Am J Hum Genet. 102:696.
8. Ladha, J. et al. (2012) Mol Cancer Res. 10:1039.

Publications for AE Binding Protein 1/ACLP (6425-AC)(1)

Publication using 6425-AC

• Sekiguchi, S;Yorozu, A;Okazaki, F;Niinuma, T;Takasawa, A;Yamamoto, E;Kitajima, H;Kubo, T;Hatanaka, Y;Nishiyama, K;Ogi, K;Dehari, H;Kondo, A;Kurose, M;Obata, K;Kakiuchi, A;Kai, M;Hirohashi, Y;Torigoe, T;Kojima, T;Osanai, M;Takano, K;Miyazaki, A;Suzuki, H; ACLP Activates Cancer-Associated Fibroblasts and Inhibits CD8+ T-Cell Infiltration in Oral Squamous Cell Carcinoma Cancers 2023-08-28 [PMID: 37686580] (Bioassay, Human)

Bioinformatics

• Uniprot:
  • Q8IUX7()